Prophylactic use of fluconazole in neutropenic cancer patients.
This study was carried out on 70 patients with haematological or solid malignancies who were receiving chemotherapy and/or radiotherapy. Forty-one patients were randomly assigned to receive fluconazole, 400 mg/day, while they were neutropenic. Systemic fungal infection developed in four of the 41 patients (9%) receiving prophylaxis in comparison to nine of 29 patients (31%) not receiving prophylaxis. The incidence of systemic fungal infection was significantly different between the groups receiving prophylaxis and those not receiving it (p < 0.05). Fluconazole was found to be effective for preventing systemic fungal infections in neutropenic patients with cancer.
Yamaç
K
K
Department of Hematology, Gazi University, Faculty of Medicine, Ankara, Turkey.
Senol
E
E
Haznedar
R
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000517:prevention & control*; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D009503:Neutropenia / Q000150:complications* / Q000209:etiology
D015725:Fluconazole